So we look forward to now bringing forward that medicine as a third indication approval for ... its world-first approval in China in 2023. The conditional nod is based on results from the phase ...
Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback